Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1801–1824 of 35,388 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Healthy
Interventions: Clopidogrel, Placebo, Omeprazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Obstructive Sleep Apnea
Interventions: Belun Ring, PSG; Device · Diagnostic Test
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Beachwood, Ohio • Cleveland, Ohio

Conditions: Melanoma
Interventions: DS-8273a, Nivolumab; Biological
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Gram-negative Bacterial Infections
Interventions: nacubactam, meropenem; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Obesity
Interventions: Pneumovax 23, Blood tests, Questionnaires; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 35 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Prediabetes, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Prediabetic State &Amp; High Risk Individuals on the Basis of Diabetes Risk Score
Interventions: Linkage to Care, Educational, Healthy Lifestyle Tools; Behavioral · Other
Lead sponsor: Xavier University of Louisiana.; Other
Eligibility: 18 Years to 99 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Total Knee Arthroplasty
Interventions: Genicular Nerve Radiofrequency Ablation; Other
Lead sponsor: University of Utah; Other
Eligibility: 30 Years to 90 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Dravet Syndrome
Interventions: Transcranial Magnetic Stimulation (TMS), Electroencephalogram (EEG); Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Months to 30 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Iron Deficiency
Interventions: Quadruple sequential Helicobacter pylori eradication + iron sulfate, Quadruple sequential Helicobacter pylori eradication therapy, Ferrous sulfate, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 36 Months to 120 Months
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Dyslipidaemias, Dyslipidemias
Interventions: 10mg atorvastatin, 80mg atorvastatin, GSK1292263 Placebo, 100mg GSK1292263, 300mg GSK1292263, 800mg GSK1292263, 10mg ezetimibe, Washout; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: Anniston, Alabama • Chula Vista, California • Stockton, California + 15 more

Conditions: Chronic Patellar Tendinopathy, Chronic PT
Interventions: platelet rich plasma, saline; Biological · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2024
U.S. locations: 2
States / cities: Madison, Wisconsin

Conditions: Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism
Interventions: PLS240, Standard of Care; Drug · Combination Product
Lead sponsor: Pathalys Pharma; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Ischemic Stroke
Interventions: intracranial angioplasty and stenting, intensive medical management; Device · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 30 Years to 80 Years
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 50
States / cities: Birmingham, Alabama • Phoenix, Arizona • Glendale, California + 38 more

Conditions: Diabetic Foot Infection, Non-healing Wound, Non-healing Diabetic Foot Ulcer
Interventions: TTAX01, Standard care; Biological · Other
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 16
States / cities: Guntersville, Alabama • Tucson, Arizona • Los Angeles, California + 12 more

Conditions: Total Knee Arthroplasty
Interventions: Legion™ CR Oxinium and CoCr Femoral Implants combined with Legion™/Genesis™ II XLPE High Flex Tibial Inserts; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 4
States / cities: Edina, Minnesota • Reno, Nevada • Greenville, South Carolina + 1 more

Conditions: Healthy Volunteers
Interventions: Abrocitinib tablet, Abrocitinib Suspension F1, Abrocitinib Suspension F2, Abrocitinib Suspension F3, Abrocitinib Suspension F4, Abrocitinib Suspension F5, Abrocitinib Suspension F6, Famotidine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Varicose Veins
Interventions: Polidocanol Endovenous Microfoam 0.125%; Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Bellevue, Washington

Conditions: Marginal Bone Level Change
Interventions: NobelActive TiUltra implant, NobelParallel CC TiUltra implants, NobelReplace CC TiUltra implants, Nobel Biocare N1 TiUltra TCC implants; Device
Lead sponsor: Nobel Biocare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 5
States / cities: Madison, Alabama • Arlington Heights, Illinois • Saint Charles, Illinois + 2 more

Conditions: Healthy Volunteers
Interventions: Venglustat, Itraconazole; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Diabetes Mellitus, High Blood Pressure, High Blood Sugar, Hypertension
Interventions: FAM ACT, I-DSMES; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years to 75 Years
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Detroit, Michigan • Pittsburgh, Pennsylvania

Conditions: Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Carcinosarcoma
Interventions: BLU-222, Carboplatin, Ribociclib, Fulvestrant; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 19
States / cities: Little Rock, Arkansas • San Francisco, California • Stanford, California + 13 more

Conditions: Healthy
Interventions: Enlicitide decanoate; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Hypertension
Interventions: Nebivolol, Atenolol, Moxifloxacin; Drug
Lead sponsor: Mylan Bertek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cancer
Interventions: [18F]F-AraG; Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

Belun Ring Validation Study for Assessment of Obstructive Sleep Apnea

Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma

A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants

Effect of Obesity on Immune Response to Pneumovax 23

Pharmacists' Delivery of Education to Prevent Diabetes in the New Orleans Hospitality Industry

Genicular Nerve Radiofrequency Ablation for Chronic Knee Pain After Total Knee Arthroplasty

Transcranial Magnetic Stimulation to Measure Cortical Excitability in Dravet Syndrome

Helicobacter Pylori Eradication Trial to Reduce Iron Deficiency in Children

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

Platelet-Rich Plasma (PRP) Injection for the Treatment of Chronic Patellar Tendinopathy

A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)

Safety and Performance Using Legion™ CR Oxinium and CoCr Femoral Implants Combined With Legion™/Genesis™ II XLPE High Flex Tibial Inserts

A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.

An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins

A Clinical Study on Implants With TiUltra Technology and Associated Prosthetic Components

A Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered Venglustat and Itraconazole in Healthy Adult Male Participants

Comparative Effectiveness of Family vs. Individually Focused Diabetes Education and Support

(VELA) Study of BLU-222 in Advanced Solid Tumors

A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)

A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo

Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans